Otsuka's Taiho buys Swiss startup Araris with three ADCs nearing the clinic
A small Swiss drug developer is being scooped up for its pipeline of three antibody-drug conjugates that offer a next-generation approach to the area of oncology R&D that has ballooned in recent years. Otsuka subsidiary ...
A small Swiss drug developer is being scooped up for its pipeline of three antibody-drug conjugates that offer a next-generation approach to the area of oncology R&D that has ballooned in recent years.
Otsuka subsidiary ...
